Regulatory MSD’s Keytruda-Padcev combo secures EC approval for MIBC Pharmaceutical Business ReviewThe authorisation applies to adults with resectable MIBC who cannot be treated with cisplatin-based chemotherapy.OncologyRead full story pharminent June 25, 2026 (Last updated: June 25, 2026) Pharmaceutical Business Review The authorisation applies to adults with resectable MIBC who cannot be treated with cisplatin-based chemotherapy. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly launches its LillyDirect sales channel in the UKNext: FDA’s uniQure, REGENXBIO reversals could bolster other near-term rare disease applications Related Stories Regulatory Celcuity gets FDA nod for first-in-class breast cancer drug pharminent July 15, 2026 Regulatory FDA clears at-home start dose for Alzheimer’s drug Leqembi pharminent July 14, 2026 Regulatory FDA posts new rejection letters days after confirming pause pharminent July 13, 2026
